ArticleAmerican journal of translational research2025
TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy and safety of TPF versus FOLFOX regimens in conversion therapy for locally unresectable advanced gastric cancer (LAUGC) and to identify prognostic factors influencing clinical outcomes.
methodsThis retrospective study analyzed 264 LAUGC patients treated with either TPF (n=140) or FOLFOX (n=124) between 2019 and 2021. Primary endpoints were objective response rate (ORR) and 1-year survival; secondary endpoints included conversion surgery rate, toxicity, and 3-year survival. Prognostic factors were evaluated using multivariate Cox regression and time-dependent ROC analyses.
resultsThe TPF group demonstrated significantly higher ORR (P=0.01) and disease control rate (DCR; P<0.001) compared to the FOLFOX group. Rates of conversion surgery (P=0.011) and R0 resection (P=0.003) were also improved. One-year survival was superior in the TPF cohort (P<0.05), whereas 3-year survival rates showed no significant difference (P>0.05). Although myelosuppression was more frequent with TPF (P=0.002), the incidence of severe adverse events was comparable between groups. Multivariate analysis identified FOLFOX regimen, elevated carcinoembryonic antigen (CEA), and N3 stage as risk factors for 1-year mortality, while higher albumin levels and lymphocyte counts were protective. Tumor size ≥5 cm and poor differentiation were associated with increased 3-year mortality risk. Albumin demonstrated strong predictive value for 1-year survival.
conclusionThe TPF regimen can effectively improve the objective response rate and short-term survival in LAUGC patients undergoing conversion therapy, with manageable myelosuppression. The analysis of prognostic risk factors facilitates individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.